Ardent Health Finalizes Separation Agreement with Former CEO Martin J. Bonick
ARDT sits 28% above its 52-week low of $7.71.
Summary
Ardent Health, Inc. disclosed the financial terms of former CEO Martin J. Bonick's separation, including a $4.842 million cash severance and non-compete clauses.
Key Events · Executive and Board Changes · ARDT
-
Former CEO Separation Terms Finalized
Details of the separation agreement with former President and CEO Martin J. Bonick were disclosed, effective June 2, 2026, following his previously announced departure.
-
Cash Severance Package
Mr. Bonick will receive a cash severance of $4.842 million, calculated as two times his annual salary and target bonus.
-
Equity Award Treatment
The agreement specifies the vesting of certain restricted stock units (RSUs) and performance-based restricted stock units (PRSUs), while other awards are forfeited.
-
Restrictive Covenants Imposed
Mr. Bonick is subject to 12-month non-competition and non-solicitation covenants following his separation date.
Analysis · ARDT · Industrial Applications And Services
This 8-K details the separation agreement for former CEO Martin J. Bonick, whose departure was previously announced on June 2, 2026. The agreement includes a cash severance package of $4.842 million, COBRA benefits, and specifies the vesting and forfeiture of his equity awards. It also imposes 12-month non-competition and non-solicitation covenants, providing clarity on the terms of his exit and resolving any outstanding uncertainty regarding the financial impact of the leadership transition.
At the time of this filing, ARDT was trading at $9.84 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.71 to $15.48. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.